OPKO Health, Inc. seeks to serve unmet patient needs through our first in class products, such as the 4Kscore® Test, comprehensive diagnostics laboratories, robust research and development pipeline, and unique pharmaceutical business solutions. The 4Kscore Test is a simple blood test that provides an accurate assessment of a man’s risk for aggressive prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore test is based on more than a decade of research and is included in current US, Canadian, and European prostate cancer early detection guidelines. 4Kscore is marketed by GenPath Urology, a division of BioReference Laboratories, an OPKO Health Company. OPKO also offers leading edge genetic testing through GeneDx, Inc. with a suite of services, including diagnostic testing for hereditary cancers, inherited cardiac disorders, metabolic disorders, mitochondrial disorders, and neurological disorders.